Low-dose metformin as a monotherapy does not reduce non-small-cell lung cancer tumor burden in mice

Search for this publication on Google Scholar
Marino, J. S., Stott Bond, N. L., Dréau, D., Marriott, I., Bennett, J. M., Turner, M. J., & Arthur, S. (2021). Low-dose metformin as a monotherapy does not reduce non-small-cell lung cancer tumor burden in mice. Biomedicines. https://doi.org/doi:10.3390/biomedicines9111685
Download PDF

Analytics

64 views ◎
24 downloads ⇓


Description

Non-small-cell lung cancer (NSCLC) makes up 80–85% of lung cancer diagnoses. Lung cancer patients undergo surgical procedures, chemotherapy, and/or radiation. Chemotherapy and radiation can induce deleterious systemic side effects, particularly within skeletal muscle. To determine whether metformin reduces NSCLC tumor burden while maintaining skeletal muscle health, C57BL/6J mice were injected with Lewis lung cancer (LL/2), containing a bioluminescent reporter for in vivo tracking, into the left lung. Control and metformin (250 mg/kg) groups received treatments twice weekly. Skeletal muscle was analyzed for changes in genes and proteins related to inflammation, muscle mass, and metabolism. The LL/2 model effectively mimics lung cancer growth and tumor burden. The in vivo data indicate that metformin as administered was not associated with significant improvement in tumor burden in this immunocompetent NSCLC model. Additionally, metformin was not associated with significant changes in key tumor cell division and inflammation markers, or improved skeletal muscle health. Metformin treatment, while exhibiting anti-neoplastic characteristics in many cancers, appears not to be an appropriate monotherapy for NSCLC tumor growth in vivo. Future studies should pursue co-treatment modalities, with metformin as a potentially supportive drug rather than a monotherapy to mitigate cancer progression.

Details
Title

Low-dose metformin as a monotherapy does not reduce non-small-cell lung cancer tumor burden in mice

Author(s)

Marino, Joseph S.
Stott Bond, Nicole L.
Dréau, Didier
Marriott, Ian
Bennett, Jeanette M.
Turner, Michael J.
Arthur, Susan

UNC Charlotte Affiliate Type

Faculty

Publisher

MDPI

Extent

1 online resource

Date Published

2021

Material Type

Journal article

Genre

articles

Resource Type

text

Abstract

Non-small-cell lung cancer (NSCLC) makes up 80–85% of lung cancer diagnoses. Lung cancer patients undergo surgical procedures, chemotherapy, and/or radiation. Chemotherapy and radiation can induce deleterious systemic side effects, particularly within skeletal muscle. To determine whether metformin reduces NSCLC tumor burden while maintaining skeletal muscle health, C57BL/6J mice were injected with Lewis lung cancer (LL/2), containing a bioluminescent reporter for in vivo tracking, into the left lung. Control and metformin (250 mg/kg) groups received treatments twice weekly. Skeletal muscle was analyzed for changes in genes and proteins related to inflammation, muscle mass, and metabolism. The LL/2 model effectively mimics lung cancer growth and tumor burden. The in vivo data indicate that metformin as administered was not associated with significant improvement in tumor burden in this immunocompetent NSCLC model. Additionally, metformin was not associated with significant changes in key tumor cell division and inflammation markers, or improved skeletal muscle health. Metformin treatment, while exhibiting anti-neoplastic characteristics in many cancers, appears not to be an appropriate monotherapy for NSCLC tumor growth in vivo. Future studies should pursue co-treatment modalities, with metformin as a potentially supportive drug rather than a monotherapy to mitigate cancer progression.

Subjects--Topics

Lungs--Cancer
Musculoskeletal system

Is Part Of

Biomedicines

Language

English

Published Version (Please cite this version)

doi:10.3390/biomedicines9111685

Permalink

http://hdl.handle.net/20.500.13093/work:206

Rights

This item may be protected by copyright and other related rights. Atkins Library provides access to this item for educational and research purposes only; other uses require the permission of the copyright holder.